The filing is routine and immaterial given the small size of the proposed sale. Watch for any acceleration of insider selling or larger filings, but no immediate action is warranted.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $17.54entry
- T+1 · 6mo ago +0.40%α −0.43% · $17.61
- T+5 · 6mo ago +5.13%α +3.63% · $18.44
- T+20 · 6mo ago +2.57%α −0.57% · $17.99
- T+60 · 4mo ago +43.90%α +40.07% · $25.24
Price Chart
How similar events traded
Executive Summary
Atlas Venture Associates XI, L.P., a major venture capital shareholder, filed a Form 144 indicating intent to sell 428 shares of Dyne Therapeutics common stock. The proposed sale is small (approx. $3.2M) relative to Dyne's $2.9B market cap and appears to be routine portfolio management, not indicative of bearish sentiment.
Key Facts
- Atlas Venture Associates XI, L.P. intends to sell 428 shares of Dyne Therapeutics common stock.
- The filing notes no other sales of the issuer's securities in the past 3 months.
- The shares were acquired via private placement on 04/26/2019.
- Proposed sale price approximately $7,477 per share, with total value around $3.2 million.
- Dyne's market cap is $2.9 billion, making this a negligible fraction of outstanding shares.
Financial Impact
Approximately $3.2 million (428 shares × ~$7,477/share)
Risk Factors
- Minimal direct impact on stock price; the sale is too small to signal distress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-031382 |
| Document: 0001628280-26-031382-index.html | 0001628280-26-031382 |
| Document: 0001628280-26-031382.txt | 0001628280-26-031382 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers